课题基金 / 基金详情

ACTG 366 NOVEL ANTIRETROVIRAL COMBINATIONS IN ADVANCED HIV DISEASE

ACTG 366 NOVEL ANTIRETROVIRAL COMBINATIONS IN ADVANCED HIV DISEASE
ACTG 366 治疗晚期艾滋病毒的新型抗逆转录病毒药物组合
批准号：
6309797
负责人：
Peter James Krause
金额：
$1.91万
依托单位：
UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2000-11-30
来源：
https://reporter.nih.gov/project-details/6309797
关键词：
2'3' dideoxycytidine 2'3' dideoxyinosine AIDS AIDS therapy adolescence (12-20) antiAIDS agent child (0-11) clinical research clinical trial phase I combination chemotherapy drug screening /evaluation human subject human therapy evaluation lamivudine nevirapine pediatric AIDS protease inhibitor ritonavir stavudine zidovudine

项目摘要

项目成果

Peter James Krause的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Some combinations of anti-HIV drugs have been shown to reduce HIV in humans. The purposes of this study are to find out if treatment with certain drug combinations will decrease the amount of HIV in the blood and how long this decrease might last, to find out if the drug combinations can be safely given to children and adolescents who have advanced HIV disease or have not benefited from other HIV treatments, and to find the right doses of these drugs when the drugs are used in combination. The medications to be studied are zidovudine, didanosine, zalcitabine, stavudine, lamivudine, nevirapine, ritonavir, and nelfinavir.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
RECURRENT LYME DISEASE
RECURRENT LYME DISEASE
RECURRENT LYME DISEASE
Recurrent Lyme Disease
海外基金